Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases

Modern Rheumatology

Volumn 17, Issue 2, 2007, Pages 131-136

  Okada, Makoto ^a   Suzuki, Kimihiro ^a   Matsumoto, Mitsuyo ^a   Nakashima, Masahiro ^a   Nakanishi, Takashi ^a   Takada, Kunio ^a   Horikoshi, Hideyuki ^a   Matsubara, Osamu ^a   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Computed tomography; KL 6; Pulmonary functioning test

Indexed keywords

AZASETRON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC CYSTITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG ALVEOLUS CARBON DIOXIDE TENSION; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; CONNECTIVE TISSUE DISEASES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 34247280461     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0554-2     Document Type: Article

References (25)

1. A Schnabel M Reuter WL Gross 1998 Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis Rheum 41 1215-20 9663478 10.1002/ 1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y 1:CAS:528:DyaK1cXkslWjtLo%3D
2. SV Kocheril BE Appleton EC Somers EA Kazerooni KR Flaherty FJ Martinez 2005 Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia Arthritis Rheum 53 549-57 16082627 10.1002/ art.21322 1:STN:280:DC%2BD2MvisValtg%3D%3D
3. GW Hunninghake AR Kalica 1995 Approaches to the treatment of pulmonary fibrosis Am J Respir Crit Care Med 151 915-8 7881692 1:STN:280:ByqC1cjksFI%3D
4. VD Steen JK Lanz Jr C Conte GR Owens TA Medsger Jr 1994 Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 37 1290-6 7945491 10.1002/art.1780370904 1:STN:280:ByqD3s3isVQ%3D
5. MA Johnson S Kwan NJ Snell AJ Nunn JH Darbyshire M Turner-Warwick 1989 Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis Thorax 44 280-8 2669218 1:STN:280:BiaA2cjktlw%3D
6. AR Eiser HM Shanies 1994 Treatment of lupus interstitial lung disease with intravenous cyclophosphamide Arthritis Rheum 37 428-31 8129799 10.1002/art.1780370318 1:STN:280:ByuC2srpvFc%3D
7. T Shinohara T Hidaka Y Matsuki T Ishizuka M Takamizawa M Kawakami 1997 Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy Intern Med 36 519-23 9240505 1:STN:280:ByiA1c3ltVU%3D
8. N Kohno S Kyoizumi Y Awaya H Fukuhara M Yamakido M Akiyama 1989 New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6 Chest 96 68-73 2661160 1:STN:280:BiaB1cbitVA%3D
9. N Kohno 1999 Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis J Med Invest 46 151-8 10687309 1:STN:280:DC%2BD3c7ltF2htw%3D%3D
10. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304
11. T Fukuda M Setoguchi K Inaba H Shoji T Tahara 1991 The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist Eur J Pharmacol 196 299-305 1654255 10.1016/0014-2999(91)90443-T 1:CAS:528:DyaK3MXkt1Wqu7c%3D
12. HA Austin 3rd JH Klippel JE Balow NG le Riche AD Steinberg PH Plotz 1986 Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs N Engl J Med 314 614-9 3511372
13. WJ McCune J Golbus W Zeldes P Bohlke R Dunne DA Fox 1988 Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus N Engl J Med 318 1423-31 3259286 1:STN:280:BieB3MnntlU%3D
14. AD Steinberg SC Steinberg 1991 Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum 34 945-50 1859488 10.1002/art.1780340803 1:STN:280:By6A3Mrmt1w%3D
15. GS Hoffman RY Leavitt TA Fleisher JR Minor AS Fauci 1990 Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide Am J Med 89 403-10 2220874 10.1016/0002-9343(90)90367-M 1:STN:280:By6D383nvFc%3D
16. M Haubitz S Schellong U Gobel HJ Schurek D Schaumann KM Koch R Brunkhorst 1998 Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study Arthritis Rheum 41 1835-44 9778225 10.1002/ 1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q 1:CAS:528:DyaK1cXmvFWmtro%3D
17. R Giacomelli G Valentini F Salsano P Cipriani P Sambo ML Conforti 2002 Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis J Rheumatol 29 731-6 11950014 1:CAS:528:DC%2BD38XjtFGltLw%3D
18. I Pakas JP Ioannidis K Malagari FN Skopouli HM Moutsopoulos PG Vlachoyiannopoulos 2002 Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J Rheumatol 29 298-304 11842824 1:CAS:528:DC%2BD38XhsF2iu78%3D
19. DJ Helfrich B Banner VD Steen TA Medsger Jr 1989 Normotensive renal failure in systemic sclerosis Arthritis Rheum 32 1128-34 2775321 10.1002/ anr.1780320911 1:STN:280:BiaA2svjs1I%3D
20. WB Gruhn JA Diaz-Buxo 1987 Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis J Rheumatol 14 1045-7 3323505 1:STN:280:BieC3MfmsFU%3D
21. Y Nawata K Kurasawa K Takabayashi S Miike N Watanabe M Hiraguri 1999 Corticosteroid resistant interstitial pneumonitis in dermatomyositis/ polymyositis: Prediction and treatment with cyclosporine J Rheumatol 26 1527-33 10405940 1:CAS:528:DyaK1MXksFemtLY%3D
22. M Okada K Suzuki T Nakanishi M Nakashima 2006 The serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases Respirology 11 509-10 16771927 10.1111/j.1440-1843.2006.00881.x
23. A Yokoyama N Kohno H Hamada M Sakatani E Ueda K Kondo 1998 Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis Am J Respir Crit Care Med 158 1680-4 9817725 1:STN:280:DyaK1M%2FjsVOlsg%3D%3D
24. A Yokoyama K Kondo M Nakajima T Matsushima T Takahashi M Nishimura 2006 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Respirology 11 217-20 10.1111/j.1440-1843.2006.00834.x
25. S Bandoh J Fujita Y Ohtsuki Y Ueda S Hojo M Tokuda 2000 Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis Ann Rheum Dis 59 257-62 10733471 10.1136/ard.59.4.257 1:CAS:528:DC%2BD3cXivFajtr8%3D